Trial · NCT07239674
Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
NCT07239674, Phase 3, Not yet recruiting, West China Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC. Trials, record NCT07239674. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07239674
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
- NCT number
- NCT07239674
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 646 participants, estimated
- Lead sponsor
- West China Hospital
- Conditions
- Intermediate-to-High Risk Differentiated Thyroid Cancer
- Interventions
- desiccated thyroid extract (DTE)+levothyroxine (L-T4)
- First posted
- 2025-11-20
- Last updated
- 2025-11-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of adequate TSH suppression | 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | Rate of adequate TSH suppression defined as TSH level reaching the preset suppression target. TSH suppression targets follow the 2023 Chinese Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer (2nd edition): during the initial treatment phase (within 1 year after surgery ± ¹³¹I therapy), serum TSH should be \< 0.1 mU/L for high-risk patients and 0.1-0.5 mU/L for intermediate-risk patients. |
| Primary | Time to TSH suppression target | 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | Median number of days from treatment initiation to the first measurement meeting TSH suppression criteria. |
| Secondary | Thyroid function test | Preoperative, 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | Thyroid function parameters (TSH, FT3, FT4, TT3, TT4) are measured at every follow-up visit to evaluate the physiological stability of hormone replacement. |
| Secondary | Symptoms and quality of life related to thyroid dysfunction | Preoperative, 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | THyPRO-39 |
| Secondary | Assessment of hair-loss severity | Preoperative, 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | Hair-pull test. |
| Secondary | Adverse events (AEs) | 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment | Adverse events (AEs) refer to any unfavorable medical occurrences that develop during the clinical trial, regardless of whether they are related to the investigational medication. They include: Thyroid-hormone-excess-related AEs * Cardiovascular system: tachycardia, angina, cardiac insufficiency, atrial fibrillation and other arrhythmias. * Musculoskeletal system: osteoporosis, fractures, bone pain. Hypersensitivity/allergic reactions |
| Secondary | DIO2 polymorphism analysis | Preoperative | Genomic DNA is extracted from pre-operative blood. The region containing the target SNP is amplified by PCR, digested with a restriction endonuclease, and genotypes are assigned after electrophoresis based on fragment sizes. The data will be used to explore the relationship between DIO2 genotype, TSH-suppression efficacy, and the FT3/FT4 ratio, providing a molecular basis for individualized therapy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07239674
GET https://conductscience.org/api/trials/v1/NCT07239674/registered